Insights

Funding momentum Kannalife has secured multiple non-dilutive grants from high-profile sources including The Michael J. Fox Foundation and NIH HEAL, indicating strong validation of its KLS-13019 program and potential for accelerated clinical development partnerships.

Neuroinflammation niche Lead candidate KLS-13019 targets neuroinflammation and mitochondrial dysfunction via mNCX-1, GPR55, and NLRP3, aligning with unmet needs in Parkinson’s disease and other neurodegenerative conditions, suggesting opportunities for sponsored research, co-development, or licensing discussions with pharma focused on neurodegenerative therapeutics.

Strategic partnerships As a subsidiary of Neuropathix with existing municipal and academic funding, Kannalife can be positioned as a collaboration-ready partner for contract research and IND-enabling studies, appealing to sponsors seeking early-stage collaboration and risk-sharing on CNS programs.

Clinical development readiness Recent high-value grants support IND-enabling work for KLS-13019, signaling progress toward clinical trials and creating revenue opportunities through sponsored trials, milestone-based collaborations, and potential licensing deals once development milestones are met.

Growth and visibility Public recognition, a focused bioscience hub location in Pennsylvania, and a lean team profile suggest agility for targeted outreach to pharmaceutical companies seeking niche cannabinoid-inspired therapeutics and opportunities to sponsor translational research or early-phase programs.

Similar companies to Kannalife Sciences, Inc.

Kannalife Sciences, Inc. Tech Stack

Kannalife Sciences, Inc. uses 8 technology products and services including Amazon Web Services, WordPress, Shopify, and more. Explore Kannalife Sciences, Inc.'s tech stack below.

Media & News

Kannalife Sciences, Inc.'s Email Address Formats

Kannalife Sciences, Inc. uses at least 3 email formats:
Kannalife Sciences, Inc. Email FormatsExamplePercentage
First@kannalife.comJohn@kannalife.com
50%
FLast@kannalife.comJDoe@kannalife.com
25%
LastF@kannalife.comDoeJ@kannalife.com
25%

Frequently Asked Questions

What is Kannalife Sciences, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Kannalife Sciences, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Kannalife Sciences, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Kannalife Sciences, Inc.'s official website is kannalife.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Kannalife Sciences, Inc. generate?

Minus sign iconPlus sign icon
As of November 2026, Kannalife Sciences, Inc.'s annual revenue is estimated to be $1M - $10M.

What is Kannalife Sciences, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
Kannalife Sciences, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Kannalife Sciences, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2026, Kannalife Sciences, Inc. has approximately 6 employees across 1 continents, including North America. Key team members include Owner: J. P. and Advisor/Shareholder: G. W. Explore Kannalife Sciences, Inc.'s employee directory with LeadIQ.

What industry does Kannalife Sciences, Inc. belong to?

Minus sign iconPlus sign icon
Kannalife Sciences, Inc. operates in the Pharmaceutical Manufacturing industry.

What technology does Kannalife Sciences, Inc. use?

Minus sign iconPlus sign icon
Kannalife Sciences, Inc.'s tech stack includes Amazon Web Services, WordPress, Shopify, Google Workspace, Mailchimp, Google Cloud, WP Engine and Vimeo.

What is Kannalife Sciences, Inc.'s email format?

Minus sign iconPlus sign icon
Kannalife Sciences, Inc.'s email format typically follows the pattern of First@kannalife.com. Find more Kannalife Sciences, Inc. email formats with LeadIQ.

How much funding has Kannalife Sciences, Inc. raised to date?

Minus sign iconPlus sign icon
As of November 2026, Kannalife Sciences, Inc. has raised $6M in funding. The last funding round occurred on Jun 25, 2024 for $1.5M.

When was Kannalife Sciences, Inc. founded?

Minus sign iconPlus sign icon
Kannalife Sciences, Inc. was founded in 2010.
Kannalife Sciences, Inc. logo

Kannalife Sciences, Inc.

Pharmaceutical ManufacturingPennsylvania, United States2-10 Employees

Kannalife Sciences, Inc. is a biopharmaceutical company focused on developing synthetic cannabinoid–inspired therapeutics for neurodegenerative and neuropathic diseases. It operates as a subsidiary of Neuropathix, Inc. and is based in Doylestown, Pennsylvania, at the Pennsylvania Biotechnology Center. Its lead candidate, KLS-13019, is designed to address drivers of neuroinflammation and mitochondrial dysfunction. It pursues globally patented therapeutic approaches within the pharmaceutical manufacturing sector and targets pathways such as mNCX-1, GPR55, and the NLRP3 inflammasome. With a lean organizational footprint, the company advances its development program toward clinical evaluation.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
3254 - Pharmaceutical and Medicine Manufacturing
Founded
2010
Employees
2-10

Section iconFunding & Financials

  • $6M

    Kannalife Sciences, Inc. has raised a total of $6M of funding over 4 rounds. Their latest funding round was raised on Jun 25, 2024 in the amount of $1.5M as a Grant.

  • $1M - $10M

    Kannalife Sciences, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.